Paper Details

  1. Home
  2. Paper Details

A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).

Author: KupersmithM, MitnickH J, PagetS A, PetersonM G, RichmondM, SpieraH, SpieraR F

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Methotrexate added to corticosteroid therapy for giant cell arteritis (GCA) did not show a corticosteroid-sparing benefit. Both groups had similar corticosteroid dose reductions and few major side effects.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To determine if methotrexate has disease-controlling and corticosteroid (cs)-sparing effects in the treatment of giant cell arteritis (GCA). METHODS: This was a randomized, controlled, double-blind trial comparing methotrexate versus placebo in addition to corticosteroid therapy in patie...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/11579707

データ提供：米国国立医学図書館（NLM）

Methotrexate in Giant Cell Arteritis: A Randomized Controlled Trial

In the realm of [rheumatology], we are constantly searching for effective treatments for inflammatory conditions like giant cell arteritis (GCA), a debilitating disease that affects the blood vessels. This study investigates the potential benefits of methotrexate, a commonly used drug for other inflammatory diseases, in treating GCA. It's like searching for a rare desert plant that could hold the key to healing.

Evaluating Methotrexate's Role in Treating GCA

The study found that methotrexate, when combined with corticosteroids, did not provide a significant benefit in terms of reducing corticosteroid dosage or improving outcomes in patients with GCA. This suggests that methotrexate may not be a suitable treatment option for GCA, as it's possible that this plant is not the one we're searching for.

Exploring Treatment Options for GCA

This research highlights the ongoing need to explore alternative treatment strategies for GCA. It's like searching for a new desert oasis – we must continue to seek out new solutions for treating this challenging disease. This study also emphasizes the importance of understanding the limitations of existing treatments and exploring new avenues for therapeutic development.

Dr.Camel's Conclusion

This study provides valuable insights into the effectiveness of methotrexate in treating GCA. It's like a desert journey, where we must be willing to adjust our course and explore new possibilities. While methotrexate may not be the answer for GCA, this study underscores the importance of continued research and exploration of novel treatment approaches to address this complex disease.

Date :
  1. Date Completed 2002-02-14
  2. Date Revised 2017-01-12
Further Info :

Pubmed ID

11579707

DOI: Digital Object Identifier

11579707

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.